Page last updated: 2024-10-16

carnitine and Diabetic Retinopathy

carnitine has been researched along with Diabetic Retinopathy in 7 studies

Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.

Research Excerpts

ExcerptRelevanceReference
"Carnitine was a major contributor to the pathway differences."5.51Arginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy. ( Brantley, MA; Burgess, LG; Cherney, EF; Chocron, IM; Ferreira, AJ; Goodale, MP; Herren, DJ; Jones, DP; Law, JC; Ma, C; Mitchell, SL; Osborn, MP; Sumarriva, K; Uppal, K; Wang, Y; Warden, C, 2019)
"Diabetic retinopathy is a common complication of type 2 diabetes mellitus (T2DM)."1.72Relationship Between Acylcarnitine and the Risk of Retinopathy in Type 2 Diabetes Mellitus. ( Fang, ZZ; Gao, XQ; Li, X; Liu, X; Wang, WY, 2022)
"Carnitine was a major contributor to the pathway differences."1.51Arginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy. ( Brantley, MA; Burgess, LG; Cherney, EF; Chocron, IM; Ferreira, AJ; Goodale, MP; Herren, DJ; Jones, DP; Law, JC; Ma, C; Mitchell, SL; Osborn, MP; Sumarriva, K; Uppal, K; Wang, Y; Warden, C, 2019)

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's1 (14.29)29.6817
2010's1 (14.29)24.3611
2020's4 (57.14)2.80

Authors

AuthorsStudies
Wang, WY1
Liu, X2
Gao, XQ1
Li, X1
Fang, ZZ1
Wang, Z2
Tang, J1
Jin, E1
Ren, C1
Li, S2
Zhang, L2
Zhong, Y1
Cao, Y1
Wang, J1
Zhou, W1
Zhao, M2
Huang, L2
Qu, J1
Qutob, HMH1
Saad, RA1
Bali, H1
Osailan, A1
Jaber, J1
Alzahrani, E1
Alyami, J1
Elsayed, H1
Alserihi, R1
Shaikhomar, OA1
Divya, KM1
Savitha, DP1
Krishna, GA1
Dhanya, TM1
Mohanan, PV1
Shah, SF1
Jafry, AT1
Hussain, G1
Kazim, AH1
Ali, M1
Rivani, E1
Endraswari, PD1
Widodo, ADW1
Khalil, MR1
Guldberg, R1
Nørgård, BM1
Uldbjerg, N1
Wehberg, S1
Fowobaje, KR1
Mashood, LO1
Ekholuenetale, M1
Ibidoja, OJ1
Romagnoli, A1
D'Agostino, M1
Pavoni, E1
Ardiccioni, C1
Motta, S1
Crippa, P1
Biagetti, G1
Notarstefano, V1
Rexha, J1
Perta, N1
Barocci, S1
Costabile, BK1
Colasurdo, G1
Caucci, S1
Mencarelli, D1
Turchetti, C1
Farina, M1
Pierantoni, L1
La Teana, A1
Al Hadi, R1
Cicconardi, F1
Chinappi, M1
Trucchi, E1
Mancia, F1
Menzo, S1
Morozzo Della Rocca, B1
D'Annessa, I1
Di Marino, D1
Choya, A1
de Rivas, B1
Gutiérrez-Ortiz, JI1
López-Fonseca, R1
Xu, S1
Cheng, B1
Huang, Z1
Liu, T1
Li, Y1
Jiang, L1
Guo, W1
Xiong, J1
Amirazodi, M1
Daryanoosh, F1
Mehrabi, A1
Gaeini, A1
Koushkie Jahromi, M1
Salesi, M1
Zarifkar, AH1
Studeny, P1
Netukova, M1
Nemcokova, M1
Klimesova, YM1
Krizova, D1
Kang, H1
Tao, Y1
Zhang, Q1
Sha, D1
Chen, Y1
Yao, J1
Gao, Y1
Liu, J1
Ji, L1
Shi, P1
Shi, C1
Wu, YL1
Wright, AI1
M El-Metwaly, N1
A Katouah, H1
El-Desouky, MG1
El-Bindary, AA1
El-Bindary, MA1
Kostakis, ID1
Raptis, DA1
Davidson, BR1
Iype, S1
Nasralla, D1
Imber, C1
Sharma, D1
Pissanou, T1
Pollok, JM1
Hughes, AM1
Sanderson, E1
Morris, T1
Ayorech, Z1
Tesli, M1
Ask, H1
Reichborn-Kjennerud, T1
Andreassen, OA1
Magnus, P1
Helgeland, Ø1
Johansson, S1
Njølstad, P1
Davey Smith, G1
Havdahl, A1
Howe, LD1
Davies, NM1
Amrillah, T1
Prasetio, A1
Supandi, AR1
Sidiq, DH1
Putra, FS1
Nugroho, MA1
Salsabilla, Z1
Azmi, R1
Grammatikopoulos, P1
Bouloumis, T1
Steinhauer, S1
Mironov, VS2
Bazhenova, TA2
Manakin, YV2
Yagubskii, EB2
Yakushev, IA1
Gilmutdinov, IF1
Simonov, SV1
Lan, K1
Yang, H1
Zheng, J1
Hu, H1
Zhu, T1
Zou, X1
Hu, B1
Liu, H1
Olokede, O1
Wu, H1
Holtzapple, M1
Gungor, O1
Kose, M1
Ghaemi, R1
Acker, M1
Stosic, A1
Jacobs, R1
Selvaganapathy, PR1
Ludwig, N1
Yerneni, SS1
Azambuja, JH1
Pietrowska, M1
Widłak, P1
Hinck, CS1
Głuszko, A1
Szczepański, MJ1
Kärmer, T1
Kallinger, I1
Schulz, D1
Bauer, RJ1
Spanier, G1
Spoerl, S1
Meier, JK1
Ettl, T1
Razzo, BM1
Reichert, TE1
Hinck, AP1
Whiteside, TL1
Wei, ZL1
Juan, W1
Tong, D1
Juan, LX1
Sa, LY1
Jie, HFM1
Xiao, G1
Xiang, LG1
Jie, HM1
Xu, C1
Yu, DN1
Yao, ZX1
Bigdeli, F1
Gao, XM1
Cheng, X1
Li, JZ1
Zhang, JW1
Wang, W2
Guan, ZJ1
Bu, Y1
Liu, KG1
Morsali, A1
Das, R1
Paul, R1
Parui, A1
Shrotri, A1
Atzori, C1
Lomachenko, KA1
Singh, AK1
Mondal, J1
Peter, SC1
Florimbio, AR1
Coughlin, LN1
Bauermeister, JA1
Young, SD1
Zimmerman, MA1
Walton, MA1
Bonar, EE1
Demir, D1
Balci, AB1
Kahraman, N1
Sunbul, SA1
Gucu, A1
Seker, IB1
Badem, S1
Yuksel, A1
Ozyazicioglu, AF1
Goncu, MT1
Zhang, H1
Zhou, H1
Deng, Z1
Luo, L1
Ong, SP1
Wang, C1
Xin, H1
Whittingham, MS1
Zhou, G1
Maemura, R1
Wakamatsu, M1
Matsumoto, K1
Sakaguchi, H1
Yoshida, N1
Hama, A1
Yoshida, T1
Miwata, S1
Kitazawa, H1
Narita, K1
Kataoka, S1
Ichikawa, D1
Hamada, M1
Taniguchi, R1
Suzuki, K1
Kawashima, N1
Nishikawa, E1
Narita, A1
Okuno, Y1
Nishio, N1
Kato, K1
Kojima, S1
Morita, K1
Muramatsu, H1
Takahashi, Y1
Yirgu, A1
Mekonnen, Y1
Eyado, A1
Staropoli, A1
Vinale, F1
Zac, J1
Zac, S1
Pérez-Padilla, R1
Remigio-Luna, A1
Guzmán-Boulloud, N1
Gochicoa-Rangel, L1
Guzmán-Valderrábano, C1
Thirión-Romero, I1
Statsenko, ME1
Turkina, SV1
Barantsevich, ER1
Karakulova, YV1
Baranova, NS1
Morzhukhina, MV1
Wang, Q1
Gu, Y1
Chen, C1
Qiao, L1
Pan, F1
Song, C1
Canetto, SS1
Entilli, L1
Cerbo, I1
Cipolletta, S1
Wu, Y2
Zhu, P1
Jiang, Y1
Zhang, X1
Xie, B1
Song, T1
Zhang, F1
Luo, A1
Xiong, X1
Han, J1
Peng, X1
Li, M1
Chen, Q1
Fang, W1
Hou, Y1
Zhu, Y1
Ye, J1
Liu, L1
Islam, MR1
Sanderson, P1
Johansen, MP1
Payne, TE1
Naidu, R1
Cao, J1
Yang, J1
Niu, X1
Zhai, Y1
Qiang, C1
Niu, Y1
Li, Z1
Dong, N1
Wen, B1
Ouyang, Z1
Zhang, Y1
Li, J2
Zhao, J1
Morici, P1
Rizzato, C1
Ghelardi, E1
Rossolini, GM1
Lupetti, A1
Gözüküçük, R1
Cakiroglu, B1
He, X1
Li, R1
Zhao, D1
Ji, X1
Fan, X1
Chen, J1
Wang, Y2
Luo, Y1
Zheng, D1
Xie, L1
Sun, S1
Cai, Z1
Liu, Q1
Ma, K1
Sun, X1
Drinkwater, JJ1
Davis, TME1
Turner, AW1
Davis, WA1
Suzuki, Y1
Mizuta, Y1
Mikagi, A1
Misawa-Suzuki, T1
Tsuchido, Y1
Sugaya, T1
Hashimoto, T1
Ema, K1
Hayashita, T1
Fort, PE1
Rajendiran, TM1
Soni, T1
Byun, J1
Shan, Y1
Looker, HC1
Nelson, RG1
Kretzler, M1
Michailidis, G1
Roger, JE1
Gardner, TW1
Abcouwer, SF1
Pennathur, S1
Afshinnia, F1
Sumarriva, K1
Uppal, K1
Ma, C1
Herren, DJ1
Chocron, IM1
Warden, C1
Mitchell, SL1
Burgess, LG1
Goodale, MP1
Osborn, MP1
Ferreira, AJ1
Law, JC1
Cherney, EF1
Jones, DP1
Brantley, MA1
Poorabbas, A1
Fallah, F1
Bagdadchi, J1
Mahdavi, R1
Aliasgarzadeh, A1
Asadi, Y1
Koushavar, H1
Vahed Jabbari, M1
Hotta, N1
Koh, N1
Sakakibara, F1
Nakamura, J1
Hamada, Y1
Hara, T1
Fukasawa, H1
Kakuta, H1
Sakamoto, N1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Renoprotection in Early Diabetic Nephropathy in Pima Indians[NCT00340678]Phase 3170 participants (Actual)Interventional1995-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Glomerular Volume

(NCT00340678)
Timeframe: 6 years after first treatment

Intervention*10^6 cubic microns (Mean)
Normoalbuminuria Losartan5.4
Normoalbuminuria Placebo5.6
Microalbuminuria Losartan6.4
Microalbuminuria Placebo7.0

Number of Participants With Decline in GFR

Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation. (NCT00340678)
Timeframe: Up to 6 years

Interventionparticipants (Number)
Normoalbuminuria Losartan2
Normoalbuminuria Placebo2
Microalbuminuria Losartan1
Microalbuminuria Placebo4

Reviews

1 review available for carnitine and Diabetic Retinopathy

ArticleYear
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12

    Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter

2022

Trials

1 trial available for carnitine and Diabetic Retinopathy

ArticleYear
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
    Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12

    Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter

2022

Other Studies

6 other studies available for carnitine and Diabetic Retinopathy

ArticleYear
Relationship Between Acylcarnitine and the Risk of Retinopathy in Type 2 Diabetes Mellitus.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; ROC Curve

2022
Metabolomic comparison followed by cross-validation of enzyme-linked immunosorbent assay to reveal potential biomarkers of diabetic retinopathy in Chinese with type 2 diabetes.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Aged; Biomarkers; Carnitine; Case-Control Studies; Chenodeoxycholic Acid; China; Citrulline; Diabete

2022
Diminished retinal complex lipid synthesis and impaired fatty acid β-oxidation associated with human diabetic retinopathy.
    JCI insight, 2021, 10-08, Volume: 6, Issue:19

    Topics: Adult; Aged; American Indian or Alaska Native; Arizona; Black or African American; Carnitine; Case-C

2021
Arginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy.
    Investigative ophthalmology & visual science, 2019, 07-01, Volume: 60, Issue:8

    Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Carnitine; Case-Control Studies; Chromatography, Liqu

2019
Determination of free L-carnitine levels in type II diabetic women with and without complications.
    European journal of clinical nutrition, 2007, Volume: 61, Issue:7

    Topics: Blood Glucose; Blood Pressure; Body Mass Index; Carnitine; Case-Control Studies; Cross-Sectional Stu

2007
Effect of propionyl-L-carnitine on oscillatory potentials in electroretinogram in streptozotocin-diabetic rats.
    European journal of pharmacology, 1996, Sep-12, Volume: 311, Issue:2-3

    Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Body Weight;

1996